San Diego Business Journal

Recent Stories

Cos. Don’t Have to Pull the Plug After Clinical Trial Failures

MEDICINE: They Can Make Aggressive Cuts, Pursue Other Avenues

Those in the science business must learn to roll with the punches when clinical trials flop, especially when the companies are public, and the failures are broadcast on a global stage, industry veterans said.

Eli Lilly to Collaborate With Institute

Sanford-Burnham Medical Research Institute will collaborate with Eli Lilly and Co. to develop immunological therapies, the companies announced.

Visa Cap May Blunt Competitive Edge

WORKFORCE: Critics Say Program Undercuts Citizens

The growing demand for highly skilled foreign workers in biotech and information technology is rekindling debate about the motivation driving companies to hire foreign talent.

Tease photo

Foundry Medical Innovations Merging With Zeis to Become Toolbox Medical Innovations

Foundry Medical Innovations, a medical and diagnostic device development company in Carlsbad, has merged with Zeis Consulting Group, an IVD clinical research firm.

Cidara Therapeutics Reports Q1 Results

Cidara Therapeutics Inc. reported May 21 a net loss of $6.7 million for the first quarter of 2015, up from a net loss of $707,000 in the same quarter of last year.

Lpath to Cut Jobs After Eye Drug Fails Study

San Diego drug developer Lpath Inc. said it would cut jobs and costs after its experimental eye drug failed a mid-stage study in patients with wet age-related macular degeneration, a leading cause of blindness in the elderly.

Companion Medical Completes Series B Financing

Companion Medical Inc., a medical device company in San Diego, has announced the completion of a series B financing, led by an investment from Eli Lilly and Co.

Tandem Diabetes Announces That Its t:flex Insulin Pump Is on the Market

Tandem Diabetes Care Inc., a medical device company in San Diego, announced Tuesday that its t:flex Insulin Pump is on the market, with shipments planned in June.

Sevion Therapeutics Raises $3.02 Million in Equity Financing

Sevion Therapeutics Inc., a biopharmaceutical company developing therapies for cancer and immunological diseases, has raised $3.02 million in equity financing according to a recent statement filed with the Securities and Exchange Commission.

Tease photo

Sorrento Therapeutics Sells Subsidiary and Cancer Drug in Deal Potentially Worth $1.3 Billion

In a deal potentially worth up to $1.3 billion, San Diego’s Sorrento Therapeutics has sold the rights to its proposed cancer treatment Cynviloq, as well as the wholly owned subsidiary that was developing the drug, to Illinois-based NantPharma.

More stories